Paul never met Andre until a few months before he closed the reverse merger. OMHE looked like a good deal when it was negotiated. Malecon Pharmacy (OMHE) was a private company with $10 million/year in revenue and almost $1 million in net income when the deal was signed. They did OK for the first year after the merger with Mike Hawkins as their interim CEO (lending Mike to them for a year was part of the original contract). Then Andre took over complete control, stopped issuing financials and went silent. It was all downhill after that.
Market Data 
Markets 
AI
